STRO Insider Trading Activity and SEC Form 4 Filings
STRO insider trading summary
No open-market insider purchases or sales of Sutro Biopharma, Inc. (STRO) have been reported on SEC Form 4 in the past 12 months.
Latest STRO insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 15, 2025 | Gregory K. Chow | CFO | Buy | $16K (19,750 @ $0.81) |
| Oct 15, 2025 | David Pauling | Chief Admin. Ofcr. & GC | Buy | $10K (12,504 @ $0.80) |
| Oct 15, 2025 | Connie Matsui | Insider | Buy | $40K (50,000 @ $0.80) |
| Oct 15, 2025 | Jane Chung | Chief Executive Officer | Buy | $10K (12,500 @ $0.80) |
| Oct 15, 2025 | Hans-Peter Gerber | Chief Scientific Officer | Buy | $14K (17,000 @ $0.80) |
| Jan 29, 2024 | Nicki Vasquez | Chief Port. Strat & Alnce Ofcr | Sell | $61K (12,185 @ $5.00) |
| Aug 28, 2023 | Brunilda Shtylla | Chief Business Officer | Sell | $73K (15,428 @ $4.71) |
| Aug 25, 2023 | Brunilda Shtylla | Chief Business Officer | Sell | $53K (11,613 @ $4.59) |
| Mar 14, 2022 | William J Newell | CEO | Buy | $78K (10,000 @ $7.75) |
| Sep 28, 2021 | Nicki Vasquez | Chief Port. Strat & Alnce Ofcr | Sell | $73K (3,906 @ $18.62) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.